DAFNA Capital Management »

AtriCure shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of AtriCure (ATRC) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in AtriCure

Tip: Access up to 7 years of quarterly data

All positions including AtriCure held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in AtriCure by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2012-06-30 $943k 98k 9.61

More positions owned by DAFNA Capital Management

Spdr S&p Biotech Etf Etf (XBI)
Stereotaxis Com New (STXS)
Revolution Medicines (RVMD)
Cytokinetics Com New (CYTK)
Merus N V (MRUS)
AtriCure (ATRC)
Ideaya Biosciences (IDYA)
Ishares Nasdaq Biotech Indx Etf (IBB)
Ascendis Pharma A/s Sponsored Adr (ASND)
Axogen (AXGN)
Blueprint Medicines (BPMC)
Xenon Pharmaceuticals (XENE)
Day One Biopharmaceuticals I (DAWN)
Syndax Pharmaceuticals (SNDX)
Biohaven (BHVN)

View all positions for DAFNA Capital Management

Top funds holding AtriCure

Vanguard Group
BlackRock
Alliancebernstein
Hood River Capital Management
Champlain Investment Partners
Macquarie Group
First Light Asset Management
Wellington Management Company
State Street Corporation
Divisadero Street Capital Management
Nuveen Asset Management
Geode Capital Management
Ubs Global Asset Management Americas
Jennifer Ranahan
FMR

View all funds holding AtriCure